Investor · 1 deal
San Francisco
Every published round Kern Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| GPN Vaccines | Series B | 7 Jun 2024 | $18m | Lead | ausceleratesa.org, Business News Australia, gpnvaccines.com |
Companies Kern Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| GPN Vaccines | 7 Jun 2024, Series B | 1 | 1 |
Fund closes reported for Kern Capital, as distinct from the investments it has made.
Companies Kern Capital has backed that another company then bought. An exit for the holding, not a deal Kern Capital did.
| Name | Role | Sources |
|---|---|---|
| Jay Kern | General Partner | Business News Australia, gpnvaccines.com |
Stories naming Kern Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GPN Vaccines, an Adelaide biotech, has closed a A$18 million Series B1 that beat its 15 million target, co-led by Forepont Capital and Mike Gregg, with Kern Capital joining as a new investor.